Home > Harmony in Hematology

Harmony in Hematology

An Alliance with 45 Participants from the public domain and 8 pharmaceutical companies.


HARMONY unites academic institutions, clinical disease networks, patient advocacy groups, clinicians, and pharmaceutical companies, as well as regulatory agencies, health technology assessment bodies, experts in economics and ethics, and information and communication technology specialists.

All 53 partners share the same goal: to address the present challenges effectively, to provide data, and to participate in communication activities. This network will build upon the work carried out by existing European and national cooperative groups.

HARMONY was initiated in January 2017 for a period of five years, and is funded through the European Union's (EU's) Innovative Medicines Initiative (IMI). Capitalizing on its strong drive to succeed, on a spirit of international cooperation, and on the availability of high-speed technologies, HARMONY will facilitate better access to therapy, improved patient care, and a higher quality of life, all accomplished in compliance with legal, ethical, and governance rules. Its results will evolutionize the treatment of hematologic malignancies (HMs).

Hematologic malignancies with a high unmet need in adult and pediatric patients are:

Overview of the HARMONY Alliance Partners.